<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524186</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000562762</org_study_id>
    <secondary_id>RPCI-I-69605</secondary_id>
    <nct_id>NCT00524186</nct_id>
  </id_info>
  <brief_title>Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer</brief_title>
  <official_title>Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      sunitinib together with combination chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sunitinib when&#xD;
      given together with irinotecan, fluorouracil, and leucovorin in treating patients with&#xD;
      advanced stomach cancer or gastroesophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of sunitinib malate when administered with FOLFIRI&#xD;
           chemotherapy comprising irinotecan hydrochloride, fluorouracil, and leucovorin calcium&#xD;
           in patients with advanced gastroesophageal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rates, overall survival, and progression-free survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine if there is a change in circulating endothelial precursor cell number and VEGF&#xD;
           expression as a result of this therapy and if these changes correlate with improved&#xD;
           response and survival.&#xD;
&#xD;
        -  Document any pharmacokinetic interactions between irinotecan hydrochloride and sunitinib&#xD;
           malate.&#xD;
&#xD;
        -  Study pharmacokinetics of sunitinib malate on day 14 (steady state) and day 42 (after 6&#xD;
           weeks of continuous dosing).&#xD;
&#xD;
      OUTLINE: Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in&#xD;
      course 1 and on days 1-28 in all subsequent courses. Patients also receive FOLFIRI&#xD;
      chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, fluorouracil IV&#xD;
      continuously over 46 hours, and leucovorin calcium IV over 2 hours beginning on days 1 and&#xD;
      15. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Blood is collected at baseline and periodically during study for pharmacokinetic and&#xD;
      biomarker correlative studies. Samples are analyzed by flow cytometry to assess circulating&#xD;
      endothelial cells and VEGF expression.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institute&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)</measure>
    <time_frame>30 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate as assessed by RECIST criteria</measure>
    <time_frame>Every 3 months up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 3 months up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating endothelial precursor cell (CEC) number</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF expression</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Taken Orally</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative Study</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative Study</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Locally advanced or unresectable gastric cancer&#xD;
&#xD;
               -  Metastatic gastric adenocarcinoma&#xD;
&#xD;
               -  Metastatic gastroesophageal junction (GEJ) adenocarcinoma&#xD;
&#xD;
                    -  Esophageal adenocarcinomas with involvement of GEJ allowed&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Symptomatic, uncontrolled CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  WBC ≥ 3,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Uncontrolled serious medical disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Coagulopathy or bleeding disorder&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to sunitinib malate or other agents used in study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Concurrent therapeutic anticoagulation allowed&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Other concurrent investigational therapy&#xD;
&#xD;
          -  Concurrent combination antiretroviral therapy in HIV-positive patients&#xD;
&#xD;
          -  Major surgery or radiotherapy within the past 3 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Boland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

